Mantle Cell

ARTICLES

Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).
Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.
The drug has been approved for treatment-naive patients who are ineligible for transplant.
Imbruvica (ibrutinib) is a first-in-class BTK inhibitor with potential for treating blood cancer, indicated for use in MCL and CLL patients.

EVENTS

January 23rd - 25th, 2014
San Francisco , CA
February 15th -18th, 2014
San Diego, CA
Compendia
Diabetes Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
$AD300x250BB$
$vacMongoViewPlus$